Management
Jörg Neermann
Ph.D.
CEO
Jörg Neermann, Ph.D.
Jörg studied Biotechnology at the Technical University of Braunschweig, Germany, and at the Massachusetts Institute of Technology (M.I.T.). He performed his Ph.D. research work in genetic engineering of mammalian cell cultures at the Gesellschaft of Biotechnologische Forschung mbH (GBF) and received his Ph.D. with summa cum laude from TU Braunschweig in 1997. In addition, he studied economics at TU Braunschweig and Harvard Business School.
After a brief stint in management consulting he started his career in life sciences venture capital in 1996 with Atlas Venture as an associate. In 1998 he joined DVC Deutsche Venture Capital, a subsidiary of Deutsche Bank, as an investment manager; there he built the Life Science franchise and became Partner in 2000 and Managing Partner in early 2002. In 2007 he joined LSP Life Sciences Partners as a Partner in their Munich office. During his time at DVC and LSP he invested as lead investor in more than 20 biotech companies and accompanied as a board member most of these companies through various financings to an IPO or M&A. In spring 2021 he joined Curexsys as CEO.
Jens Gruber
Ph.D.
CSO
Jens Gruber, Ph.D.
Jens studied „Molecular Biology“ at the International Max-Planck Research School in Göttingen and received his PhD with summa cum laude for studies on RNA interference at the Max-Planck Institute for Biophysical Chemistry in 2005. After postdoc positions in Germany (Max-Planck Society) and the Netherlands (AMC, University of Amsterdam) he led the research group “Medical RNA Biology” at the German Primate Center. During his career in academia, Jens received grants from multiple national and international organizations (DFG, BMBF, Leibniz Society, Max-Planck-Society, Life Science Foundation, Elsbeth-Bonhoff Foundation, Brazilian cNPQ and Colombian COLCIENCIAS), co-founded a biotech start-up (VD2Tec), was elected to the Young Leaders in Science Program (Schering Foundation), became a full GGNB (Göttingen Graduate School for Neurosciences and Molecular Biosciences) member and published numerous scientific papers and patents. In 2020, Jens co-founded the Curexsys GmbH and is now active as managing director and chief scientific officer.
Christian Eckert
Ph.D.
COO
Christian Eckert, Ph.D., COO
Christian studied biology and biochemistry at the University of Wurzburg, Germany, and performed his Ph.D.and post-doc work at the department of pharmacology at LMU Munich. He then joined the Munich based Biotech start-up company KInaxo as senior scientist and team leader for proteomics and metabolomics. After the acquisition of Kinaxo by Evotec he became project leader for assay development as well as for collaborations and innovation projects. In 2016 he moved on to Medigene, where he led the overall project management. In 2019 he joined BMS (Juno Therapeutics GmbH), where he was responsible GMP manufacturing, external collaborations and various steering committees.
Board Members
Michael Shalmi
M.D., MBA
Chairman
Michael Shalmi
M.D., MBA
Chairman
Michael holds a medical doctorate degree from the University of Copenhagen and an MBA from the Scandinavian International Management Institute. Between 1994 and 2009 he held various positions at Novo Nordisk A/S, most recently as vice president of global development and clinical operations management. Between 2009 and 2019 he led the large investment group of Novo Holdings A/S and was as Managing Director responsible for Principal Investments. He served on the boards of various private and public Biotech companies.
Werner Lanthaler
D.Sc., MBA
CEO of Evotec SE
Dr. Werner Lanthaler
MBA
CEO of Evotec SE
Werner is Chief Executive Officer (CEO) of Evotec since 2009. Between 2000 and 2009 he was Chief Financial Officer (CFO) of Vienna based Intercell AG. During that time Intercell developed to a global vaccine player and went public in 2005. Prior to that he served as Director of the Federation of Austrian Industry and as Senior Management Consultant at McKinsey & Company. He holds a doctorate degree in economics from Vienna University, a Master’s degree from Harvard University and a degree in Psychology.
(www.evotec.com)
René Faber
Ph. D.
Executive board member of Sartorius AG
René Faber,
Ph.D.
Executive board member of Sartorius AG
René is member of the executive board of Sartorius AG and leads the bioprocess solutions division at Sartorius. He is also Vice President for Marketing Filtration Technologies at Sartorius Stedim Biotech. He started his career at Sartorius R&D in 2004. Before that he worked for two years at Vivascience. René holds a Ph.D. in polymer chemistry from the Technical University of Munich.
(www.sartorius.com)
Herbert Stadler
Ph.D.
Serial biotech entrepreneur
Herbert Stadler,
Ph.D.
Serial biotech entrepreneur
Over the last two decades, Herbert has built a track record as one of Germany’s most active biotech entrepreneurs. He founded and co-founded several companies including Biometra GmbH, Ribonetics GmbH, HepaVec AG, IBA GmbH, DeveloGen AG and Stage GmbH. Herbert Stadler is a neurochemist by training. He obtained his Ph.D. at the Freie University of Berlin, obtained his postdoctoral lecture qualification („Habilitation“) at the University of Göttingen and headed the Molecular Neurobiology Group at the Max-Planck Institute of Biophysical Chemistry in Göttingen.
Scientific Advisory Board
t.b.a.
Our Team
